Global Diabetes Care Devices Market Outlook, 2031
The Global Diabetes Care Devices Market is segmented into By Product Type (Blood Glucose Monitoring Systems (Self-Monitoring Blood Glucose (SMBG), Continuous Glucose Monitoring (CGM)), Insulin Delivery Devices (Insulin Pumps, Insulin Pens, Needles, Syringes)); By Disease Type (Type 1 Diabetes, Type 2 Diabetes)); By End User (Home/Self-Care, Hospitals, Diagnostic Centers, Ambulatory Surgical Centers); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
- Bonafide Research
- 21-10-2026
- Pages : 197
- Figures : 36
- Tables : 94
- Region : Global
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The Global Diabetes Care Devices Market is expected to cross 70.73 Billion market size by 2031, with 10.12% CAGR by 2026-31, driven by the rising prevalence of diabetes.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 40.21 Billion
- Market Size (2031) USD 70.73 Billion
- CAGR (2026-2031) 10.12%
- Largest MarketNorth America
- Fastest Market Asia-Pacific
- Format
Featured Companies
- 1. Medtronic
- 2. Abbott Laboratories
- 3. B. Braun Melsungen AG
- 4. Nipro Corporation
- 5. Insulet Corporation
- 6. Tandem Diabetes Care
- 7. SOOIL Development Co., Ltd
- 8. Owen Mumford Ltd
- 9. F. Hoffmann-La Roche AG,
- More...
Diabetes Care Devices Market Analysis
The global diabetes care devices market encompasses medical instruments and specialized tools utilized for monitoring, managing, and treating diabetes mellitus. The market comprises self-monitoring blood glucose (SMBG) meters, continuous glucose monitoring (CGM) systems, insulin pumps, smart insulin pens, and essential testing consumables. This sector is highly relevant in global public health as it directly empowers patients to manage glycemic variability, preventing severe acute and chronic vascular complications. Its importance is underscored by the shift toward real-time telemetry, automated insulin delivery, and artificial intelligence-driven predictive analytics that streamline remote care and minimize clinical hospitalizations. Growth drivers for this market include the escalating global prevalence of type 1 and type 2 diabetes driven by aging demographics, sedentary lifestyles, and urban dietary shifts alongside soaring demand for minimally invasive wearable sensors. Furthermore, rising personal disposable incomes, expanding healthcare coverage, and rapid technological innovations in smart, connected delivery systems act as major catalysts. Prominent global organizations, such as the International Diabetes Federation (IDF), the American Diabetes Association (ADA), and the World Health Organization (WHO) through its Global Diabetes Compact, actively shape this landscape. Their activities involve establishing standardized clinical management guidelines, raising early screening awareness, advocating for expanded diagnostic access, and supporting international policy frameworks aimed at improving device affordability in underserved regions. Recent commercial activities include extensive research and development investments into non-invasive sensing technology, strategic clinical partnerships between CGM and insulin pump manufacturers, and aggressive cross-border acquisitions to integrate digital therapeutics into comprehensive health management ecosystems. According to the research report, “Global Diabetes Care Devices Market Overview, 2031” published by Bonafide Research, the Global Diabetes Care Devices Market is expected to cross 70.73 Billion market size by 2031, with 10.12% CAGR by 2026-31..Dominant industry leaders include Abbott Laboratories, Dexcom, Medtronic, Insulet Corporation, Tandem Diabetes Care, Roche, and Ypsomed. Major commercial developments feature Abbott’s FreeStyle Libre and Dexcom’s G-series wearers, alongside automated closed-loop "artificial pancreas" systems pairing algorithms with subcutaneous sensors. Significant facts reveal that Type 2 diabetes management represents over 60% of total device utilization, while CGMs are rapidly outpacing traditional finger-stick SMBG strips due to patient preference for real-time glycemic telemetry. Tremendous growth opportunities exist in integrating artificial intelligence for predictive hypo- and hyperglycemia alerts, expanding non-invasive optical sensing technology, and tapping into high-growth emerging economies across the Asia-Pacific region. A rigorous analysis of the supply chain highlights a multi-tiered architecture dependent on specialized sub-component sourcing, high-precision manufacturing, and cold-chain logistics. At the upstream stage, key inputs encompass micro-electronics, microfluidic chips, biocompatible polymers, biosensor enzymes (such as glucose oxidase), and specialty medical adhesives. Midstream operations involve cleanroom semiconductor assembly, automated plastic injection molding, enzymatic surface coating, and calibration. Crucially, the supply chain requires stringent regulatory validation under ISO 13485 standards before entering downstream distribution. Finished devices move through direct-to-patient e-commerce channels, hospital networks, specialized durable medical equipment (DME) distributors, and retail pharmacy chains. Temperature-controlled storage and rapid fulfillment logistics are vital for maintaining the shelf-life and chemical stability of diagnostic enzyme strips and sensor filaments, ensuring reliable delivery to end-users globally.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Escalating global prevalence of diabetes and aging demographics: The ongoing global health crisis surrounding both Type 1 and Type 2 diabetes serves as the primary catalyst for market expansion. Sedentary lifestyles, urban dietary changes, increasing obesity rates, and an expanding global aging population have led to a sharp rise in diabetes diagnoses worldwide. Managing diabetes requires continuous biological feedback to prevent both short-term emergencies, such as severe hypoglycemia, and long-term vascular or microvascular complications. As a result, healthcare systems, insurance providers, and patients are prioritizing continuous, accurate diagnostic monitoring and efficient therapeutic delivery tools, creating a sustained high volume of demand for glucose sensors, testing strips, smart pens, and automated pumps.• Accelerated adoption of continuous glucose monitoring (CGM) over traditional finger-stick systems: A major behavioral and technology-driven shift in clinical care is the transition from conventional self-monitoring blood glucose (SMBG) finger-stick meters to Continuous Glucose Monitoring (CGM) systems. CGMs provide real-time, uninterrupted insights into glycemic variability without requiring frequent painful skin pricks, significantly enhancing patient compliance and quality of life. Furthermore, expanding reimbursement coverage for CGM systems across key regions especially for non-insulin dependent Type 2 patients and high-risk populations has drastically lowered out-of-pocket expenses, unlocking substantial commercial growth across both developed and developing healthcare markets.
Market Challenges
• High upfront costs and disparate global reimbursement frameworks: Despite the advanced capabilities of modern diabetes care technology, high direct purchasing costs and recurring consumable expenses (such as frequent replacement sensors, infusion sets, and specialized cartridges) remain a formidable barrier to adoption. In many emerging economies and low-to-middle-income countries, public health coverage for advanced diabetes care devices is limited or nonexistent, leaving patients reliant on out-of-pocket spending. Even within developed economies, strict reimbursement criteria set by national healthcare systems and private insurers often limit access to advanced continuous glucose monitors and automated insulin delivery pumps primarily to severe or Type 1 cases, restricting broader market penetration.• Complex regulatory requirements, data privacy, and cybersecurity concerns: Diabetes care devices operate in a strictly regulated environment, requiring rigorous clinical trial performance, biosafety verification, and continuous post-market surveillance across regulatory agencies such as the US FDA, European Medicines Agency (EMA), and National Medical Products Administration (NMPA). Furthermore, as diabetes care hardware increasingly relies on Bluetooth telemetry, cloud connectivity, smartphone integration, and automated algorithm execution, devices become vulnerable to cybersecurity risks and data privacy violations. Manufacturers face complex compliance hurdles regarding sensitive health data management (under regulations such as HIPAA and GDPR) and must continuously upgrade software protocols to protect connected delivery systems against malicious cyber threats or algorithm failures.
Market Trends
• Evolution of automated insulin delivery (AID) Systems and closed-loop artificial pancreas technology: A dominant technological trend in diabetes management is the integration of CGM sensors, control algorithms, and smart insulin pumps to form Automated Insulin Delivery (AID) systems, often referred to as closed-loop or artificial pancreas systems. These automated setups evaluate real-time sensor measurements and dynamically adjust background insulin delivery without requiring manual patient input. By reducing the cognitive burden on patients and minimizing human error during meal planning or nighttime sleeping hours, these closed-loop ecosystems represent the state-of-the-art benchmark for therapeutic compliance and clinical outcomes.• Integration of smart connectivity, mobile apps, and AI-driven predictive analytics: Modern diabetes management tools are increasingly converging with digital health platforms, wearable technology, and cloud-based analytics. Modern smart insulin pens and continuous sensors automatically sync real-time glycemic data to smartphone apps, enabling remote monitoring by caregivers and treating physicians. Concurrently, manufacturers are integrating artificial intelligence and machine learning algorithms into patient software to offer predictive alerts forecasting potential hyper- or hypoglycemic events hours before they happen based on historical patterns, meal intake, physical activity, and biological feedback. This shift toward proactive, data-driven disease management is reshaping clinical approaches to chronic care.
Diabetes Care Devices Segmentation
| By Product Type | Blood Glucose Monitoring Systems | |
| Insulin Delivery Devices | ||
| By Disease Type | Type 1 Diabetes | |
| Type 2 Diabetes | ||
| By End User | Home/Self-Care | |
| Hospitals | ||
| Diagnostic Centers | ||
| Ambulatory Surgical Centers | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| MEA | United Arab Emirates | |
| Saudi Arabia | ||
| South Africa | ||
Insulin delivery devices play an important role in diabetes care because insulin must be administered in a controlled and consistent manner to replace insufficient insulin production or compensate for the body's inability to use insulin effectively. These devices include insulin pens, syringes, insulin pumps, and automated insulin delivery systems that combine insulin administration with glucose monitoring technologies. Their practical importance is particularly evident in type 1 diabetes, where insulin treatment is essential for survival, and in type 2 diabetes, where some patients eventually require insulin as the disease progresses and other treatments become insufficient. Insulin pens have become useful in routine treatment because they are portable, relatively simple to operate, and designed to support accurate dose selection. Prefilled and disposable pen formats can also reduce preparation steps compared with drawing insulin from a vial, although the choice depends on the patient's prescription, affordability, and access to supplies. Insulin pumps offer another approach by delivering insulin continuously beneath the skin, with additional doses administered around meals when required. Some advanced systems can communicate with continuous glucose monitors and adjust insulin delivery according to glucose readings and programmed treatment settings. These technologies can help eligible patients manage changing insulin requirements during meals, physical activity, sleep, and everyday routines. Hospitals and outpatient diabetes clinics also depend on insulin delivery equipment for treatment initiation, dose adjustment, patient education, and the management of acute metabolic complications. The recurring need for insulin, compatible needles or infusion sets, reservoirs, and other consumables supports continued use beyond the initial device purchase. Nevertheless, insulin delivery devices do not replace glucose monitoring, clinical supervision, or individualized treatment planning. The position of type 2 diabetes within the diabetes care devices market reflects the scale of the condition, its gradual development, and the continuing need to monitor changes in blood glucose throughout a person's life. According to the US Centers for Disease Control and Prevention, approximately 90% to 95% of Americans with diabetes have type 2 diabetes, illustrating how strongly this disease category influences demand for diabetes management solutions in a major healthcare market. Unlike type 1 diabetes, which involves the destruction of insulin-producing pancreatic cells, type 2 diabetes generally develops when the body becomes resistant to insulin and cannot produce enough insulin to maintain normal glucose levels. Its development is associated with several interacting factors, including excess body weight, physical inactivity, increasing age, family history, and metabolic abnormalities. Because symptoms can emerge gradually or remain unnoticed for years, some individuals receive a diagnosis only after routine testing or when complications prompt medical investigation. Once diagnosed, patients may require blood glucose meters, test strips, lancets, continuous glucose monitoring systems, and other tools selected according to their treatment plans. Management can involve dietary changes, physical activity, oral medicines, injectable therapies, or insulin, depending on disease progression and individual clinical circumstances. The need for devices is therefore not restricted to people receiving insulin; glucose monitoring can also help healthcare professionals and patients understand how meals, exercise, medicines, illness, and daily routines affect blood glucose. Continuous glucose monitoring offers additional information about glucose patterns and fluctuations, while connected applications can help users record readings and communicate information to healthcare teams. The growing emphasis on early diagnosis, preventive healthcare, weight management, and the reduction of complications such as cardiovascular disease, kidney damage, nerve injury, and vision loss further reinforces the importance of sustained diabetes management. Type 2 diabetes can also affect younger people, although it remains more common among adults. Hospitals occupy a central position in diabetes care because they manage patients whose treatment needs extend beyond routine blood glucose testing and everyday disease management. Individuals may arrive at emergency departments with severe hyperglycemia, hypoglycemia, diabetic ketoacidosis, or other complications requiring rapid assessment and closely supervised treatment. Hospitals also care for people with diabetes who are admitted for unrelated conditions, including infections, cardiovascular problems, kidney disorders, and surgical procedures, because illness, changes in food intake, stress, and certain medicines can substantially affect glucose levels. These circumstances create a practical need for glucose meters, compatible testing supplies, continuous glucose monitoring technologies where clinically appropriate, insulin administration equipment, and infusion systems. Hospital teams use blood glucose measurements to guide treatment decisions, assess responses to medicines, and identify dangerous fluctuations that require intervention. Insulin may be administered through injections or controlled infusion according to the patient's condition and the hospital's treatment protocols. Device requirements also extend to intensive care units, operating theatres, maternity services, emergency departments, and general medical wards, where patient monitoring and treatment must be coordinated among doctors, nurses, pharmacists, and laboratory personnel. Hospitals further contribute to diabetes device adoption by diagnosing previously unrecognized cases, educating newly diagnosed patients, demonstrating the correct use of monitoring equipment, and helping individuals transition from supervised treatment to home-based management. Patients with complex medical needs may also receive specialist assessments to determine whether continuous glucose monitoring or an insulin pump is appropriate for their circumstances. In addition, hospitals operate procurement departments, clinical engineering services, infection-control programmes, and established purchasing procedures that support the acquisition, maintenance, and safe use of medical equipment. Their recurring requirement for testing supplies and treatment-related consumables adds to their importance as institutional purchasers. Hospital pharmacies have an important place in diabetes device distribution because they operate within healthcare institutions where treatment decisions, prescriptions, medication reviews, and patient education are closely connected. When a patient is diagnosed with diabetes during an admission or requires a change in treatment, the hospital pharmacy can help coordinate the supply of prescribed medicines and associated products needed to implement the clinical plan. Depending on hospital purchasing arrangements, product availability, and local regulations, these supplies may include blood glucose meters, test strips, lancets, insulin pens, needles, insulin syringes, and selected continuous glucose monitoring or insulin delivery products. Their role is particularly relevant when patients begin insulin treatment, require supervised dose adjustments, or need instructions on using injection equipment and monitoring supplies safely. Pharmacists can explain prescribed product use, storage requirements, handling precautions, and the importance of using compatible accessories, while referring clinical questions to the treating team when necessary. Hospital pharmacies also work with procurement departments and approved suppliers to manage product selection, inventory, storage conditions, and the availability of essential medicines and supplies. These processes matter because insulin and certain other temperature-sensitive products require appropriate storage, while shortages of testing consumables can interfere with a patient's established management routine. At discharge, pharmacy services may help patients understand their prescriptions, identify the supplies they need at home, and clarify how to obtain repeat supplies through an appropriate outpatient channel. This connection between treatment initiation and ongoing care can make hospital pharmacies an important distribution point in market classifications that emphasize institutional purchasing or hospital-linked dispensing. Nevertheless, diabetes devices are also distributed through community pharmacies, specialist suppliers, online retailers, and direct-to-consumer arrangements where permitted. Many monitoring devices require specific prescriptions or reimbursement authorization, and more complex technologies may involve specialist training and dedicated supplier support.
to Download this information in a PDF
Diabetes Care Devices Market Regional Insights
North America's leading position in the diabetes care devices market is closely connected to the way diabetes is diagnosed, treated, and managed across its healthcare systems, particularly in the United States and Canada. The International Diabetes Federation identifies the North America and Caribbean region as having a substantial diabetes burden and the highest diabetes-related healthcare expenditure among its regional groupings, reflecting the considerable resources devoted to managing the condition. The United States is especially influential because diabetes affects a large population, while established hospitals, specialist endocrinology practices, outpatient clinics, pharmacies, and home healthcare services create multiple settings in which monitoring and treatment devices are used. The region also has an established medical technology sector that develops and supplies blood glucose meters, continuous glucose monitoring systems, insulin pumps, connected diabetes management software, and automated insulin delivery technologies. These products serve different clinical needs, from routine monitoring with finger-stick testing to more detailed tracking of glucose fluctuations and technology-assisted insulin administration. The US Food and Drug Administration has established regulatory pathways for diabetes devices, including insulin pumps and automated insulin dosing systems, helping define safety and performance requirements for products marketed in the country. Another important factor is the presence of reimbursement arrangements and private insurance plans that may cover eligible devices for qualifying patients, although coverage rules, deductibles, eligibility criteria, and out-of-pocket expenses vary considerably. • USA: The United States holds a prominent position in the North American diabetes care devices market because several healthcare and technological factors operate together within its healthcare system. One important driver is the number of people living with diabetes. According to the US Centers for Disease Control and Prevention, approximately 40.1 million Americans had diagnosed or undiagnosed diabetes in 2023, representing around 12% of the population. The agency also reported a substantial population with prediabetes, demonstrating the scale of the country's ongoing need for diabetes prevention, detection, and long-term management.
to Download this information in a PDF
Key Development
- August 2026the U.S. FDA authorized Abbott Laboratories' Libre Duo 10 Day system, marking the first wearable device that simultaneously and continuously tracks both blood sugar and ketone levels.
- September 2025Medtronic received U.S. FDA clearance for integration of the MiniMed 780G insulin pump with Abbott’s Instinct CGM sensor and also secured approval for use in adults with insulin-requiring Type 2 diabetes. The approval significantly expanded the company’s automated insulin delivery portfolio and strengthened the partnership between Medtronic and Abbott.
- April 2025Abbott entered a landmark agreement to integrate data from its Libre CGM systems into Epic’s EHRs using Aura software, streamlining provider workflows and enhancing real-time diabetes management.
- April 2025Medtronic received FDA clearance to pair its Simplera Sync sensor with selected insulin pumps, reinforcing its integrated-system roadmap.
- April 2025Dexcom secured FDA authorization for the G7 15 Day CGM, extending its sensor life and improving inventory turns.
- February 2025DexCom, Inc. launched Dexcom ONE+ in Spain, Belgium, and Poland. It is a customizable continuous glucose monitoring solution consisting of a wearable sensor, a transmitter, and a smartphone-compatible app. The device can be worn on three sites in the body. The water-resistant sensor measures blood glucose levels and sends these CGM readings to smartphones compatible with the Dexcom One application.
- February 2025Tandem’s Control-IQ+ algorithm gained FDA clearance for Type 2 diabetes, opening a substantial new revenue stream for the company.
- January 2025Tandem Diabetes Care collaborated with the University of Virginia Center for Diabetes Technology in a multi-year partnership to advance fully automated closes-loop insulin delivery research.
- December 2024Abbott and Dexcom signed a ten-year cross-license accord, removing litigation costs and accelerating product innovation.
- November 2024Medtronic launched an upgraded InPen app, setting the stage for a Simplera CGM-enhanced smart-MDI ecosystem.
- October 2024Senseonics received FDA clearance for the Eversense 365, the first implantable sensor approved for annual wear.
- October 2024Ascensia Diabetes Care introduced the Eversense 365 CGM system in the US, the only one-year continuous glucose monitor. Developed by Senseonics and recently FDA-approved, it offers long-term accuracy with minimal disruptions for people with type 1 and type 2 diabetes aged 18 and older.
Companies Mentioned
- Medtronic
- Abbott Laboratories
- B. Braun Melsungen AG
- Nipro Corporation
- Insulet Corporation
- Tandem Diabetes Care
- SOOIL Development Co., Ltd
- Owen Mumford Ltd
- F. Hoffmann-La Roche AG,
- Ypsomed AG
- LifeScan, Inc
- DexCom, Inc
- Changsha Sinocare Inc.
- i-SENS, Inc.
- Biosensors International Group, Ltd.
- Arkray
- AgaMatrix
- Embecta
- Senseonics
- ACON Laboratories
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Global Diabetes Care Devices Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Region
- 6.3. Market Size and Forecast, By Geography
- 6.4. Market Size and Forecast, By Product Type
- 6.4.1. Market Size and Forecast, By Blood Glucose Monitoring Systems
- 6.4.2. Market Size and Forecast, By Insulin Delivery Devices
- 6.5. Market Size and Forecast, By Disease Type
- 6.6. Market Size and Forecast, By End User
- 6.7. Market Size and Forecast, By Distribution Channel
- 7. North America Diabetes Care Devices Market Outlook
- 7.1. Market Size By Value
- 7.2. Market Share By Country
- 7.3. Market Size and Forecast, By Product Type
- 7.4. Market Size and Forecast, By Disease Type
- 7.5. Market Size and Forecast, By End User
- 7.6. Market Size and Forecast, By Distribution Channel
- 7.7. United States Diabetes Care Devices Market Outlook
- 7.7.1. Market Size by Value
- 7.7.2. Market Size and Forecast By Product Type
- 7.7.3. Market Size and Forecast By Disease Type
- 7.7.4. Market Size and Forecast By End User
- 7.8. Canada Diabetes Care Devices Market Outlook
- 7.8.1. Market Size by Value
- 7.8.2. Market Size and Forecast By Product Type
- 7.8.3. Market Size and Forecast By Disease Type
- 7.8.4. Market Size and Forecast By End User
- 7.9. Mexico Diabetes Care Devices Market Outlook
- 7.9.1. Market Size by Value
- 7.9.2. Market Size and Forecast By Product Type
- 7.9.3. Market Size and Forecast By Disease Type
- 7.9.4. Market Size and Forecast By End User
- 8. Europe Diabetes Care Devices Market Outlook
- 8.1. Market Size By Value
- 8.2. Market Share By Country
- 8.3. Market Size and Forecast, By Product Type
- 8.4. Market Size and Forecast, By Disease Type
- 8.5. Market Size and Forecast, By End User
- 8.6. Market Size and Forecast, By Distribution Channel
- 8.7. Germany Diabetes Care Devices Market Outlook
- 8.7.1. Market Size by Value
- 8.7.2. Market Size and Forecast By Product Type
- 8.7.3. Market Size and Forecast By Disease Type
- 8.7.4. Market Size and Forecast By End User
- 8.8. United Kingdom (UK) Diabetes Care Devices Market Outlook
- 8.8.1. Market Size by Value
- 8.8.2. Market Size and Forecast By Product Type
- 8.8.3. Market Size and Forecast By Disease Type
- 8.8.4. Market Size and Forecast By End User
- 8.9. France Diabetes Care Devices Market Outlook
- 8.9.1. Market Size by Value
- 8.9.2. Market Size and Forecast By Product Type
- 8.9.3. Market Size and Forecast By Disease Type
- 8.9.4. Market Size and Forecast By End User
- 8.10. Italy Diabetes Care Devices Market Outlook
- 8.10.1. Market Size by Value
- 8.10.2. Market Size and Forecast By Product Type
- 8.10.3. Market Size and Forecast By Disease Type
- 8.10.4. Market Size and Forecast By End User
- 8.11. Spain Diabetes Care Devices Market Outlook
- 8.11.1. Market Size by Value
- 8.11.2. Market Size and Forecast By Product Type
- 8.11.3. Market Size and Forecast By Disease Type
- 8.11.4. Market Size and Forecast By End User
- 8.12. Russia Diabetes Care Devices Market Outlook
- 8.12.1. Market Size by Value
- 8.12.2. Market Size and Forecast By Product Type
- 8.12.3. Market Size and Forecast By Disease Type
- 8.12.4. Market Size and Forecast By End User
- 9. Asia-Pacific Diabetes Care Devices Market Outlook
- 9.1. Market Size By Value
- 9.2. Market Share By Country
- 9.3. Market Size and Forecast, By Product Type
- 9.4. Market Size and Forecast, By Disease Type
- 9.5. Market Size and Forecast, By End User
- 9.6. Market Size and Forecast, By Distribution Channel
- 9.7. China Diabetes Care Devices Market Outlook
- 9.7.1. Market Size by Value
- 9.7.2. Market Size and Forecast By Product Type
- 9.7.3. Market Size and Forecast By Disease Type
- 9.7.4. Market Size and Forecast By End User
- 9.8. Japan Diabetes Care Devices Market Outlook
- 9.8.1. Market Size by Value
- 9.8.2. Market Size and Forecast By Product Type
- 9.8.3. Market Size and Forecast By Disease Type
- 9.8.4. Market Size and Forecast By End User
- 9.9. India Diabetes Care Devices Market Outlook
- 9.9.1. Market Size by Value
- 9.9.2. Market Size and Forecast By Product Type
- 9.9.3. Market Size and Forecast By Disease Type
- 9.9.4. Market Size and Forecast By End User
- 9.10. Australia Diabetes Care Devices Market Outlook
- 9.10.1. Market Size by Value
- 9.10.2. Market Size and Forecast By Product Type
- 9.10.3. Market Size and Forecast By Disease Type
- 9.10.4. Market Size and Forecast By End User
- 9.11. South Korea Diabetes Care Devices Market Outlook
- 9.11.1. Market Size by Value
- 9.11.2. Market Size and Forecast By Product Type
- 9.11.3. Market Size and Forecast By Disease Type
- 9.11.4. Market Size and Forecast By End User
- 10. South America Diabetes Care Devices Market Outlook
- 10.1. Market Size By Value
- 10.2. Market Share By Country
- 10.3. Market Size and Forecast, By Product Type
- 10.4. Market Size and Forecast, By Disease Type
- 10.5. Market Size and Forecast, By End User
- 10.6. Market Size and Forecast, By Distribution Channel
- 10.7. Brazil Diabetes Care Devices Market Outlook
- 10.7.1. Market Size by Value
- 10.7.2. Market Size and Forecast By Product Type
- 10.7.3. Market Size and Forecast By Disease Type
- 10.7.4. Market Size and Forecast By End User
- 10.8. Argentina Diabetes Care Devices Market Outlook
- 10.8.1. Market Size by Value
- 10.8.2. Market Size and Forecast By Product Type
- 10.8.3. Market Size and Forecast By Disease Type
- 10.8.4. Market Size and Forecast By End User
- 10.9. Colombia Diabetes Care Devices Market Outlook
- 10.9.1. Market Size by Value
- 10.9.2. Market Size and Forecast By Product Type
- 10.9.3. Market Size and Forecast By Disease Type
- 10.9.4. Market Size and Forecast By End User
- 11. Middle East & Africa Diabetes Care Devices Market Outlook
- 11.1. Market Size By Value
- 11.2. Market Share By Country
- 11.3. Market Size and Forecast, By Product Type
- 11.4. Market Size and Forecast, By Disease Type
- 11.5. Market Size and Forecast, By End User
- 11.6. Market Size and Forecast, By Distribution Channel
- 11.7. United Arab Emirates (UAE) Diabetes Care Devices Market Outlook
- 11.7.1. Market Size by Value
- 11.7.2. Market Size and Forecast By Product Type
- 11.7.3. Market Size and Forecast By Disease Type
- 11.7.4. Market Size and Forecast By End User
- 11.8. Saudi Arabia Diabetes Care Devices Market Outlook
- 11.8.1. Market Size by Value
- 11.8.2. Market Size and Forecast By Product Type
- 11.8.3. Market Size and Forecast By Disease Type
- 11.8.4. Market Size and Forecast By End User
- 11.9. South Africa Diabetes Care Devices Market Outlook
- 11.9.1. Market Size by Value
- 11.9.2. Market Size and Forecast By Product Type
- 11.9.3. Market Size and Forecast By Disease Type
- 11.9.4. Market Size and Forecast By End User
- 12. Competitive Landscape
- 12.1. Competitive Dashboard
- 12.2. Business Strategies Adopted by Key Players
- 12.3. Key Players Market Share Insights and Analysis, 2025
- 12.4. Key Players Market Positioning Matrix
- 12.5. Porter's Five Forces
- 12.6. Company Profile
- 12.6.1. Abbott
- 12.6.1.1. Company Snapshot
- 12.6.1.2. Company Overview
- 12.6.1.3. Financial Highlights
- 12.6.1.4. Geographic Insights
- 12.6.1.5. Business Segment & Performance
- 12.6.1.6. Product Portfolio
- 12.6.1.7. Key Executives
- 12.6.1.8. Strategic Moves & Developments
- 12.6.2. F. Hoffmann-La Roche
- 12.6.3. Medtronic
- 12.6.4. Insulet
- 12.6.5. Arkray
- 12.6.6. B. Braun Melsungen AG
- 12.6.7. Sinocare
- 12.6.8. AgaMatrix
- 12.6.9. Nipro
- 12.6.10. SD Biosensor
- 12.6.11. Owen Mumford
- 12.6.12. Dexcom
- 12.6.13. Embecta
- 12.6.14. i-SENS
- 12.6.15. LifeScan IP Holdings
- 12.6.16. Senseonics
- 12.6.17. Ypsomed
- 12.6.18. Tandem Diabetes Care
- 12.6.19. Sooil Development
- 12.6.20. ACON Laboratories
- 13. Strategic Recommendations
- 14. Annexure
- 14.1. FAQ`s
- 14.2. Notes
- 15. Disclaimer
Table 2: Influencing Factors for Diabetes Care Devices Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Diabetes Care Devices Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Diabetes Care Devices Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 8: Global Diabetes Care Devices Market Size and Forecast, By Blood Glucose Monitoring Systems (2020 to 2031F) (In USD Billion)
Table 9: Global Diabetes Care Devices Market Size and Forecast, By Insulin Delivery Devices (2020 to 2031F) (In USD Billion)
Table 10: Global Diabetes Care Devices Market Size and Forecast, By Disease Type (2020 to 2031F) (In USD Billion)
Table 11: Global Diabetes Care Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 12: Global Diabetes Care Devices Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 13: North America Diabetes Care Devices Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 14: North America Diabetes Care Devices Market Size and Forecast, By Disease Type (2020 to 2031F) (In USD Billion)
Table 15: North America Diabetes Care Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 16: North America Diabetes Care Devices Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 17: United States Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 18: United States Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 19: United States Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 20: Canada Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 21: Canada Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 22: Canada Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 23: Mexico Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 24: Mexico Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 25: Mexico Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 26: Europe Diabetes Care Devices Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 27: Europe Diabetes Care Devices Market Size and Forecast, By Disease Type (2020 to 2031F) (In USD Billion)
Table 28: Europe Diabetes Care Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 29: Europe Diabetes Care Devices Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 30: Germany Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 31: Germany Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 32: Germany Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 33: United Kingdom (UK) Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 34: United Kingdom (UK) Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 35: United Kingdom (UK) Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 36: France Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 37: France Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 38: France Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 39: Italy Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 40: Italy Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 41: Italy Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 42: Spain Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 43: Spain Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 44: Spain Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 45: Russia Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 46: Russia Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 47: Russia Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 48: Asia-Pacific Diabetes Care Devices Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 49: Asia-Pacific Diabetes Care Devices Market Size and Forecast, By Disease Type (2020 to 2031F) (In USD Billion)
Table 50: Asia-Pacific Diabetes Care Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 51: Asia-Pacific Diabetes Care Devices Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 52: China Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 53: China Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 54: China Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 55: Japan Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 56: Japan Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 57: Japan Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 58: India Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 59: India Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 60: India Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 61: Australia Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 62: Australia Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 63: Australia Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 64: South Korea Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 65: South Korea Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 66: South Korea Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 67: South America Diabetes Care Devices Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 68: South America Diabetes Care Devices Market Size and Forecast, By Disease Type (2020 to 2031F) (In USD Billion)
Table 69: South America Diabetes Care Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 70: South America Diabetes Care Devices Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 71: Brazil Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 72: Brazil Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 73: Brazil Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 74: Argentina Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 75: Argentina Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 76: Argentina Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 77: Colombia Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 78: Colombia Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 79: Colombia Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 80: Middle East & Africa Diabetes Care Devices Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 81: Middle East & Africa Diabetes Care Devices Market Size and Forecast, By Disease Type (2020 to 2031F) (In USD Billion)
Table 82: Middle East & Africa Diabetes Care Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 83: Middle East & Africa Diabetes Care Devices Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 84: United Arab Emirates (UAE) Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 85: United Arab Emirates (UAE) Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 86: United Arab Emirates (UAE) Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 87: Saudi Arabia Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 88: Saudi Arabia Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 89: Saudi Arabia Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 90: South Africa Diabetes Care Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 91: South Africa Diabetes Care Devices Market Size and Forecast By Disease Type (2020 to 2031F) (In USD Billion)
Table 92: South Africa Diabetes Care Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 93: Competitive Dashboard of top 5 players, 2025
Table 94: Key Players Market Share Insights and Analysis for Diabetes Care Devices Market 2025
Figure 2: Market attractiveness Index, By Region 2031F
Figure 3: Market attractiveness Index, By Segment 2031F
Figure 4: Global Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Diabetes Care Devices Market Share By Region (2025)
Figure 6: North America Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Diabetes Care Devices Market Share By Country (2025)
Figure 8: US Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Diabetes Care Devices Market Share By Country (2025)
Figure 13: Germany Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Diabetes Care Devices Market Share By Country (2025)
Figure 21: China Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Diabetes Care Devices Market Share By Country (2025)
Figure 28: Brazil Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Diabetes Care Devices Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Diabetes Care Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Diabetes Care Devices Market
Diabetes Care Devices Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (21 October, 2026)
- Notify To Team (21 October, 2026)
- Report updation (22 October, 2026)
- Report Quality Check (22 October, 2026)
- Report Dispatch (23 October, 2026)
- Hard Copy
Recently Viewed Products
Global Diabetes Care Devices Market Outlook, 2031
We are friendly and approachable, give us a call.